Predictors of alpha-lipoic acid treatment efficacy in diabetic polyneuropathy of the lower limbs

Terapevticheskii Arkhiv

Volumn 77, Issue 10, 2005, Pages 15-19

  Bregovsky, V B ^a   Posokhina, O V ^a   Karpova, I A ^a  

^a NONE

Author keywords

Alpha lipoic acid; Diabetic polyneuropathy; Predictors of efficacy; Treatment

Indexed keywords

ANTIOXIDANT; THIOCTIC ACID;

ADULT; ARTICLE; COMPARATIVE STUDY; DIABETIC NEUROPATHY; ELECTROPHYSIOLOGY; FEMALE; HOSPITALIZATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LEG; MALE; METABOLISM; MIDDLE AGED; PAIN; PATHOPHYSIOLOGY; PERCEPTIVE THRESHOLD; PREDICTION AND FORECASTING; REGRESSION ANALYSIS; TIME; TREATMENT OUTCOME; VIBRATION;

ADULT; ANTIOXIDANTS; DIABETES MELLITUS, TYPE 1; DIABETIC NEUROPATHIES; ELECTROPHYSIOLOGY; FEMALE; HUMANS; LOWER EXTREMITY; MALE; MIDDLE AGED; PAIN; PREDICTIVE VALUE OF TESTS; REGRESSION ANALYSIS; SENSORY THRESHOLDS; SEVERITY OF ILLNESS INDEX; THIOCTIC ACID; TIME FACTORS; TREATMENT OUTCOME; VIBRATION;

EID: 28144455725     PISSN: 00403660     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Ametov A., Barinov A., Dyck P. et al. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid. The SYDNEY trial. Diabetes Care 2003; 26: 770-776.
2. Hahm J., Kim B., Kim K. Clinical experience with thioctacid (thioctic acid) in the treatment of distal symmetric polyneuropathy in Korean diabetic patients. J. Diabetes Compl. 2004: 18: 79-85.
3. Duby J., Campbell R., Setter S. et al. Diabetic neuropathy: an intensive review. Am. J. Hlth-Syst. Pharm. 2004; 61: 160-173.
4. Reljanovich M. et al. Treatment of diabetic periferal neuropathy with the anti-oxidant tioctic acid (α-lipoic acid). A two-year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Free Radic. Biol. Med. 1999; 31: 171-179.
5. Ziegler D. et al. Treatment of symptomatic diabetic polyneuropathy with the anti-oxidant α-lipoic acid. A 7-month multicenter randomized controlled trial (ALADIN III Study). Diabetes Care 1999; 22: 1296-1301.
6. Pfeifer M., Schumer M. Clinical trials of diabetic neuropathy: past, present, and future. Diabetes 1995; 44: 1355-1361.
7. Boulton A., Kubrusly D., Bowker J. et al. Impaired vibratory perception and diabetic foot ulceration. Diabet. Med. 1986; 3: 335-337.
8. Young M., Breddy J., Veves A., Boulton A. The prediction of diabetic foot ulceration using vibration perception thresholds. A prospective study. Diabetes Care 1994; 17: 557-560.
9. Dyck P. Detection, characterization and staging of polyneuropathy: assessed in diabetics. Muscle Nerve 1988; 11: 21-32.
10. Dyck P., Davies J., Wilson D. et al. Risk factors for severity of diabetic polyneuropathy. Intensive longitudinal assessment of the Rochester Diabetic Neuropathy Study cohort. Diabetes Care 1999; 19: 229-239.
11. Young M., Boulton A., Macleod A. et al. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 1993; 36: 150-154.
12. International guidelines on the out-patient management of diabetic peripheral neuropathy. Abingdon: The Medicine Group (Education) Ltd.; 1998.
13. Sosenko J., Boulton A., Gardia M. et al. The association between symptomatic sensory neuropathy and body stature in diabetic patients. Diabetes Res. Clin. Pract. 1988; 4: 95-98.
14. Ziegler D., Nowak H., Kempler P. et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet. Med. 2004; 21: 114-121.
15. Negrisanu G., Rosu M., Bolte B. et al. Effects of 3-month treatment with the antioxidant alpha-lipoic acid in diabetic peripheral neuropathy. Rom. J. Intern. Med. 1999; 37: 297-306.
16. The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 1993; 329: 977-986.
17. Tesfaye S., Stevens L., Stephenson J. et al. and the EURODIAB IDDM Study Group. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM complications Study. Diabetologia 1996; 39: 1377-1384.